Abstract: This invention relates to a monoclonal antibody against a human HIG-1 polypeptide, the antibody binding to at least one epitope included in the amino acid sequence at positions 1-19 of a human HIG-1 polypeptide; an antibody fragment derived from the antibody; a DNA comprising a base sequence encoding a variable region of the antibody; an expression vector comprising the DNA; a cell line producing the antibody; a reagent for detecting a human HIG-1 polypeptide comprising the antibody or the antibody fragment, and a method for detecting a human HIG-1 polypeptide using the antibody or the antibody fragment.

Abstract: A motion control device of a vehicle comprises: a steering angle controller which controls a steering angle of a steered wheel so that an actual turning controlling variable becomes a target turning controlling variable; and a braking force controller which controls a vehicle braking force so that the actual turning controlling variable becomes the target turning controlling variable. The control of the steering angle controller is stopped by detecting a timing with which the braking force controller detects an oversteering state of the vehicle to start a braking force control.

Abstract: This invention relates to a monoclonal antibody against a human HIG-1 polypeptide, the antibody binding to at least one epitope included in the amino acid sequence at positions 1-19 of a human HIG-1 polypeptide; an antibody fragment derived from the antibody; a DNA comprising a base sequence encoding a variable region of the antibody; an expression vector comprising the DNA; a cell line producing the antibody; a reagent for detecting a human HIG-1 polypeptide comprising the antibody or the antibody fragment, and a method for detecting a human HIG-1 polypeptide using the antibody or the antibody fragment.

Abstract: A motion control device of a vehicle comprises: a steering angle controller which controls a steering angle of a steering wheel so that an actual turning control variable becomes a target turning control variable; and a braking force controller which controls a vehicle braking force so that the actual turning control variable becomes the target turning control variable. The braking force controller selectively uses, as a steering angle signal for control, a first steering angle signal which reflects a steering angle compensation quantity compensated by the steering angle controller at the time of the oversteering of the vehicle is reflected, and a second steering angle signal which does not reflect the steering angle compensation quantity.

Abstract: A motion control device of a vehicle comprises: a steering angle controller which controls a steering angle of a steered wheel so that an actual turning controlling variable becomes a target turning controlling variable; and a braking force controller which controls a vehicle braking force so that the actual turning controlling variable becomes the target turning controlling variable. The control of the steering angle controller is stopped by detecting a timing with which the braking force controller detects an oversteering state of the vehicle to start a braking force control.

Abstract: A motion control device of a vehicle comprises: a steering angle controller which controls a steering angle of a steering wheel so that an actual turning control variable becomes a target turning control variable; and a braking force controller which controls a vehicle braking force so that the actual turning control variable becomes the target turning control variable. The braking force controller selectively uses, as a steering angle signal for control, a first steering angle signal which reflects a steering angle compensation quantity compensated by the steering angle controller at the time of the oversteering of the vehicle is reflected, and a second steering angle signal which does not reflect the steering angle compensation quantity.

Abstract: To provide cytokine production inhibitors useful as preventive or therapeutic medicines for diseases accompanied by hyperactivated immune functions. A cytokine production inhibitor containing, as an active ingredient, a thioamide compound represented by the formula (I) or a salt thereof: wherein A is N, NO, C—NO2 or C—CN; Hal is a halogen; M1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, amino, O, S, SO or SO2; M2 is amino, O, S or a single bond; R1 is a halogen, alkyl or the like; each of R2, R3, R4 and R5 is independently H, alkyl or the like; R6 is a halogen, alkyl or the like; Cy is cycloalkyl, cycloalkenyl, aryl or heterocyclyl; each of k, p and q is independently an integer of from 0 to 3; and r is an integer of from 0 to 5.

Abstract: To provide cytokine production inhibitors useful as preventive or therapeutic medicines for diseases accompanied by hyperactivated immune functions. A cytokine production inhibitor containing, as an active ingredient, a thioamide compound represented by the formula (I) or a salt thereof: wherein A is N, NO, C—NO2 or C—CN; Hal is a halogen; M1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, amino, O, S, SO or SO2; M2 is amino, O, S or a single bond; R1 is a halogen, alkyl or the like; each of R2, R3, R4 and R5 is independently H, alkyl or the like; R6 is a halogen, alkyl or the like; Cy is cycloalkyl, cycloalkenyl, aryl or heterocyclyl; each of k, p and q is independently an integer of from 0 to 3; and r is an integer of from 0 to 5.

Abstract: The present invention provides a cytokine production inhibitor containing as an active ingredient an aniline derivative of the formula (I) or a salt thereof: [wherein A is CO or SO2; Cy is an aryl group or a heterocyclic group; each of R1 and R2 which are independent of each other, is a halogen atom, a cyano group, a nitro group, an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, a cycloalkyl group which may be substituted, a cycloalkenyl group which may be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an amino group which may be substituted or a —B-Q group; R3 is a -M1-M2-R5 group; R4 is a hydrogen atom or an alkyl group which may be substituted; x is an integer of from 0 to 5; y is an integer of from 0 to 4; and z is an integer of from 0 to 1].

Abstract: The present invention provides a preventive or therapeutic medicine for diabetes containing as an active ingredient a fused-heterocyclic compound of the formula (I?) or its salt: [wherein G is CN, NO2, CO2R4, CHO, SO2NRaRb or CONRaRb; R1 is a halogen atom, a —O—R5 group or a —S—R5 group; R2 is a halogen atom, a —O—R5 group (wherein R5 is as defined above) or an amino group which may be substituted; and each of R8 and R10 which are independent of each other, is a hydrogen atom, a halogen atom or an alkyl group].

Abstract: The present invention provides a cytokine production inhibitor containing as an active ingredient an aniline derivative of the formula (I) or a salt thereof: 1

Abstract: The present invention provides a preventive or therapeutic medicine for diabetes containing as an active ingredient a fused-heterocyclic compound of the formula (I′) or its salt: 1

Abstract: Process for producing a nitroetheneamine derivative or its stereoisomer, its tautomer or a salt thereof comprising reacting a compound of the formula with a compound of the formula R6—CH2NO2 to obtain a compound of the formula and reacting the resulting compound with a compound of the formula

Abstract: The present invention provides a medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): 1

Abstract: A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): wherein the substituents are as defined in the disclosure, its stereoisomers, its tautomers or a salt thereof.

Abstract: A method for conveniently and quickly determining the viable cell count and/or survival ratio of cells. This method comprises measuring the fluorescence intensity of a test sample subjected to a treatment with a fluorescent probe for nucleic acid capable of exclusively staining dead cells and the fluorescence intensity of the test sample subjected to not only the treatment with the above-mentioned probe but also another treatment of damaging cell membrane and them comparing these intensities.

Abstract: An immuno-suppressive agent containing, as an effective component, an, enopyranose derivative of the following formula (I) or its salt: ##STR1## wherein R.sup.1 is a hydrogen atom, alkyl which may be substituted, alkenyl, alkynyl, --OSO.sub.2 R.sup.7, a halogen atom, --OCOR.sup.7, --NHCOR.sup.8, alkoxy, phenyl which may be substituted or a saccharose residue, R.sup.2 is a hydrogen atom or alkyl, R.sup.3 is a hydrogen atom or a halogen atom, R.sup.4 is a hydrogen atom, --COR.sup.9, silyl which may be substituted or alkyl which may be substituted, one of R.sup.5 and R.sup.6 is hydroxyl, alkoxy which may be substituted, a saccharose residue, cycloalkyloxy which may be substituted or --OCOR.sup.10 and the other is a hydrogen atom or alkyl which may be substituted, or R.sup.4 and R.sup.5 together form a single bond, while R.sup.6 is a hydrogen atom or alkyl which may be substituted, each of R.sup.7, R.sup.9 and R.sup.10 is alkyl or phenyl which may be substituted, R.sup.